4//SEC Filing
Umstead John W. V 4
Accession 0000950170-24-107791
CIK 0001560241other
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 4:15 PM ET
Size
14.5 KB
Accession
0000950170-24-107791
Insider Transaction Report
Form 4
Umstead John V.
Chief Financial Officer
Transactions
- Disposition to Issuer
Common Stock
2024-09-18−168,387→ 19,331 total - Disposition from Tender
Common Stock
2024-09-18−19,331→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2024-09-18−74,500→ 0 totalExercise: $2.97Exp: 2034-01-03→ Common Stock (74,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2024-09-18−6,000→ 0 totalExercise: $5.73Exp: 2033-01-03→ Common Stock (6,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2024-09-18−100,000→ 0 totalExercise: $3.27Exp: 2033-03-15→ Common Stock (100,000 underlying)
Footnotes (4)
- [F1]Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration").
- [F2](Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
- [F3]Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration.
- [F4]Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.
Documents
Issuer
G1 Therapeutics, Inc.
CIK 0001560241
Entity typeother
Related Parties
1- filerCIK 0001967910
Filing Metadata
- Form type
- 4
- Filed
- Sep 17, 8:00 PM ET
- Accepted
- Sep 18, 4:15 PM ET
- Size
- 14.5 KB